ASH Annual Meeting and Exposition | Conference

Mezigdomide Shows Encouraging Activity With Dexamethasone in Heavily Pretreated Patients With Multiple Myeloma

December 11th 2022

Mezigdomide showed notable clinical activity and a manageable safety profile when combined with dexamethasone in patients with triple-class relapsed or refractory multiple myeloma.

Zilovertamab/Ibrutinib Elicits Durable Responses With Favorable Tolerability in MCL and CLL

December 11th 2022

The combination of zilovertamab and ibrutinib resulted in promising clinical response and progression-free survival rates and showcased a tolerable toxicity profile in patients with mantle cell lymphoma and chronic lymphocytic leukemia.

Rapcabtagene Autoleucel Induces Deep, Durable Responses in Relapsed/Refractory DLBCL

December 11th 2022

The CD19-targeted CAR T-cell therapy rapcabtagene autoleucel was found to be well tolerated and to yield durable responses in patients with relapsed/refractory diffuse large B-cell lymphoma who had undergone 2 or more prior lines of therapy.

Magrolimab Plus Azacitidine and Venetoclax Produces Promising Responses in Newly Diagnosed, High-Risk AML

December 11th 2022

The addition of magrolimab to azacitidine and venetoclax produced high complete response rates and was well tolerated as first-line therapy in patients with high-risk de novo and secondary acute myeloid leukemia regardless of TP53 mutation status.

Crovalimab Achieves Stable Hemolysis Control, Transfusion Avoidance in Paroxysmal Nocturnal Hemoglobinuria

December 11th 2022

Crovalimab led to rapid and stable hemolysis control and transfusion avoidance, with no new safety signals, in Chinese patients with paroxysmal nocturnal hemoglobinuria.

Iberdomide Alone or in Combination With Anti-CD20 Monoclonal Antibodies Shows Early Efficacy in R/R Lymphoma

December 11th 2022

Iberdomide monotherapy or in combination with anti-CD20 antibodies was well tolerated and found to elicit encouraging responses in patients with relapsed or refractory lymphoma.

Frontline Ibrutinib/Venetoclax Elicits Responses in Waldenström Macroglobulinemia, But Has Safety Concerns

December 11th 2022

The combination of ibrutinib and venetoclax produced rapid and deep responses in previously untreated patients with Waldenström macroglobulinemia but there was a higher-than-anticipated rate of ventricular arrhythmia that prompted stopping treatment.

Zanubrutinib Delivers Durable Disease Control in Relapsed/Refractory MZL

December 11th 2022

Zanubrutinib sustained high response rates and led to durable disease control with low incidence of hypertension and atrial fibrillation in patients with relapsed/refractory marginal zone lymphoma, according to findings from the final analysis of the phase 2 MAGNOLIA trial.

Ziftomenib Showcases Clinical Activity, Favorable Tolerability in Relapsed/Refractory AML

December 11th 2022

Ziftomenib monotherapy had a manageable toxicity profile and provided pronounced antileukemic activity when given at a 600-mg dose in heavily pretreated patients with relapsed or refractory acute myeloid leukemia.

Dr Phillips on Glofitamab Monotherapy in Relapsed/Refractory MCL

December 11th 2022

Tycel Phillips, MD, MPH, discusses the investigation of glofitamab monotherapy in relapsed/refractory mantle cell lymphoma.

Dr Shadman on Zanubrutinib in Acalabrutinib-Intolerant Patients With B-cell Malignancies

December 11th 2022

Mazyar Shadman, MD, MPH, discusses the examination of zanubrutinib in patients with B-cell malignancies who were intolerant to acalabrutinib.

Pirtobrutinib Shows High Response Rates in Heavily Pretreated Waldenström Macroglobulinemia

December 11th 2022

The non-covalent BTK inhibitor pirtobrutinib showed high levels of response in heavily pretreated patients with Waldenström macroglobulinemia, regardless of prior treatment with a covalent BTK inhibitor.

Forimtamig Produces High ORR With IV and Subcutaneous Delivery in Relapsed/Refractory Multiple Myeloma

December 10th 2022

The GPRC5D- and CD3-directed bispecific antibody forimtamig led to high response rates in patients with relapsed or refractory multiple myeloma regardless of subcutaneous or intravenous administration, according to updated findings from a phase 1 dose-escalation study.

Rituximab/Lenalidomide Shows Sustained PFS Benefit in Indolent Non-Hodgkin Lymphoma

December 10th 2022

The combination of rituximab and lenalidomide maintained improved progression-free survival compared with rituximab alone in patients with relapsed/refractory indolent non-Hodgkin lymphoma, according to 5-year findings from the phase 3 AUGMENT trial.

Teclistamab Triplet Shows Encouraging Responses and Safety in Relapsed/Refractory Multiple Myeloma

December 10th 2022

Administration of teclistamab in combination with daratumumab and lenalidomide demonstrated promising overall response rates and tolerability in patients with relapsed/refractory multiple myeloma who had prior lenalidomide exposure, according to initial data from the phase 1b MajesTEC-2 trial.

Elranatamab Shows Promise for Penta/Triple-Refractory Myeloma

December 10th 2022

Treatment with the CD3/BCMA bispecific antibody elranatamab elicited an objective response rate by blinded independent central review of 61.0% in patients with penta- or triple-class refractory multiple myeloma who had not received a prior BCMA-targeted therapy.

Lintuzumab-Ac225 With Intensive Chemo Has Encouraging Efficacy Signal in High-risk AML

December 10th 2022

Sequential administration of lintuzumab-Ac225 after salvage chemotherapy proved to be safe and feasible, and to result in high response and minimal residual disease negativity rates in high-risk patients with relapsed/refractory acute myeloid leukemia.

Talquetamab Continues to Show Robust Efficacy With Acceptable Safety in Heavily Pretreated Multiple Myeloma

December 10th 2022

Talquetamab elicited overall response rates of higher than 70% when administered in weekly or every-other-week schedules in heavily pretreated patients with relapsed or refractory multiple myeloma.

Olverembatinib Benefit Holds Up in BCR-ABL1 T315I-Mutant, TKI-Resistant CML

December 10th 2022

Olverembatinib was found to uphold clinical benefit and continued to have an acceptable safety profile in patients with BCR-ABL1 T315I-mutant chronic myeloid leukemia -chronic phase or -acute phase that is resistant to TKIs.

Intensive Remission Induction Chemo Prior to alloHCT Does Not Confer Survival Advantage in R/R AML

December 10th 2022

Watchful waiting followed by sequential conditioning prior to allogeneic hematopoietic cell transplantation provided similar overall survival and leukemia-free survival to that achieved with intensive remission induction chemotherapy comprised of high-dose cytarabine and mitoxantrone followed by allogeneic hematopoietic cell transplantation in patients with relapsed or refractory acute myeloid leukemia.